TAE Technologies, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TAE Technologies, Inc.
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
Easton capital has secured roughly $20 million for a “special situations” fund of unusual design. The new fund is a five-year commitment between general partners and limited partners with the potential for three one-year extensions. Limited partners estimate the average life of a typical venture fund to be roughly 15 years. Easton Capital’s fund will be concluded in half the time.
Brief summaries of recent medtech market and industry developments. This month we cover Edwards Lifescience's Sapien TAVI device, and news from emerging neurostimulation companies.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
- Other Names / Subsidiaries
- TAE Life Sciences
- Tri Alpha Energy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.